In this expert opinion, Zamas Lam reviews the advantages and disadvantages of lipid nanoparticles (LNPs) and viral vectors for gene-based therapeutic delivery, including their immunogenicity risks, transduction efficiency and manufacturing considerations.
Meet the Subject Matter Expert
Zamas Lam
SVP and Global Head of Bioanalytical & Preclinical Development
QPS Holdings, LLC (DE, USA)
Zamas is the Senior Vice President of Preclinical Development at QPS (DE, USA) and is trained in mass spectrometry, carbohydrates and glycoproteins. Zamas is one of the world’s few high-resolution mass spectrometrists by training and by trade, with a passion for biologics mass spectrometry and gene therapy. Since graduate school, he keeps thinking that it will be fun to work on a gene level in drug discovery and development versus at the protein level or at the metabolite level!
Viral vectors (e.g., AAV and lentivirus) and lipid nanoparticles (LNPs) are the two dominant delivery modalities for gene-based therapeutics, each with distinct strengths and constraints. LNPs have advanced rapidly and are preferred when scalable, chemically defined manufacturing and repeat dosing are priorities and when transient expression (e.g., mRNA or genome-editing components) is desirable; however, LNPs face biodistribution and potency limitations. Viral vectors remain widely used because they achieve high in vivo transduction and, in some settings, durable expression, but they are limited by immunogenicity, re-dosing constraints, manufacturing complexity and cargo-size limits.
This article provides a detailed comparison of these platforms and will be followed by additional articles on the bioanalysis of LNP delivery for gene-based therapeutics, including assessments of systemic exposure, biodistribution, and immunogenicity for both LNP components and the delivered cargo.
LNPs and their advantages
Low immunogenicity and non-integration
LNPs are non-viral and non-infectious, exhibiting lower immunogenicity than viral vectors, which supports repeat dosing, particularly useful for chronic indications. They deliver transient cargo (e.g., mRNA) without genomic integration, reducing the risk of insertional mutagenesis associated with integrating vectors.
Scalable, tunable manufacturing
LNP limitations
Biodistribution and intracellular barriers
Early non-viral approaches performed well in vitro but showed markedly reduced potency in vivo due to barriers such as limited endosomal escape and nuclear entry. Many LNP systems exhibit imperfect targeting and systemic distribution, commonly accumulating in the liver and facing dose-limiting toxicity. Systemic administration is constrained by rapid hepatic filtration, limited transport across the blood-brain barrier for neurological indications, and endosomal sequestration that prevents timely payload release.
Transient expression
Because LNPs most commonly deliver mRNA, expression is transient; typically, mRNA delivered by LNPs produces peak protein expression 24–48 hours post administration. This makes them well-suited to vaccines and many genome-editing workflows where off-target editing can be minimized. However, this significantly limits their applications in chronic protein replacement, structural tissue regeneration or CNS disorders.
Viral vector advantages
High in vivo transduction
Viral vectors achieve efficient cell entry and gene delivery across relevant tissues, producing higher transduction than many non-viral systems. Transduction efficiency varies by serotype, dose, route of administration and tissue-specific barriers. Vectors such as AAVs typically achieve 30–80% transduction efficiency in target tissues post local administration, for example, through subretinal injection for retinal gene therapy.
Durable expression (integrating vectors)
Serotype-dependent tropism and protection
Clinical and regulatory precedent
Viral vectors benefit from decades of development, including approved products and substantial regulatory familiarity across indications. The US FDA and EMA have established clear guidance for viral vector characterization, including capsid identity and purity, vector genome titer, empty:full capsid ratio, potency assays, etc.
Viral vector limitations
Immunity and re-dosing
Manufacturing and cargo capacity
Viral vector supply is constrained by limited cargo capacity (e.g., AAV packages only ~4.7–5.0 kb) and complex, biologically driven production that is often time-consuming and expensive, making clinical-grade material difficult to scale to large patient populations. Clinical-grade manufacturing involves 2–3 months of upstream production, 1–2 months of downstream purification and 1–2 months of quality control testing, making their cost per dose significantly higher than LNPs.
Summary
LNPs are well-suited to applications where scalable, chemically defined manufacturing and repeat dosing are priorities and where transient delivery of nucleic-acid cargo is sufficient; however, their efficacy is limited by biodistribution and intracellular delivery barriers. Viral vectors are selected when high in vivo transduction and durable expression are required, but they are constrained by immunogenicity (including re-dosing challenges), cargo-size limits and manufacturing complexity.
Modality selection should be guided by multiple interdependent factors: the required duration of expression (transient vs. sustained vs. permanent), target tissue and route of administration, tolerability and re-dosing needs, patient eligibility considerations (including pre-existing immunity), and the ability to manufacture adequate clinical-grade supply at a scale and cost compatible with the target population.
